Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) PT at $17.67

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $17.67.

Several research firms have recently commented on ATEC. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Piper Sandler raised their price objective on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. Barclays lifted their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. Finally, StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th.

Alphatec Stock Performance

NASDAQ:ATEC traded up $0.22 on Tuesday, hitting $9.75. The stock had a trading volume of 1,409,281 shares, compared to its average volume of 2,030,491. Alphatec has a 52-week low of $4.88 and a 52-week high of $13.79. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -7.62 and a beta of 1.20. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business's 50-day simple moving average is $10.47 and its two-hundred day simple moving average is $9.32.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. As a group, research analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Insider Transactions at Alphatec

In other news, CEO Patrick Miles sold 50,000 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00. Following the sale, the chief executive officer now directly owns 6,152,544 shares in the company, valued at approximately $74,015,104.32. This represents a 0.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now owns 502,311 shares of the company's stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 337,083 shares of company stock valued at $3,825,680. 22.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alphatec

Several institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its holdings in Alphatec by 1.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company's stock valued at $4,577,000 after buying an additional 15,577 shares during the period. BNP Paribas Financial Markets increased its position in Alphatec by 73.7% during the third quarter. BNP Paribas Financial Markets now owns 21,603 shares of the medical technology company's stock valued at $120,000 after acquiring an additional 9,165 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Alphatec by 28.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,068 shares of the medical technology company's stock valued at $195,000 after acquiring an additional 7,825 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Alphatec by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 201,672 shares of the medical technology company's stock worth $1,121,000 after acquiring an additional 5,883 shares during the last quarter. Finally, Centiva Capital LP purchased a new position in shares of Alphatec during the 3rd quarter worth about $210,000. 66.35% of the stock is owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.